Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ganaxolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Ovid Therapeutics
Deal Size : $7.0 million
Deal Type : Agreement
Ovid Therapeutics Enters Agreement with Immedica Pharma
Details : The agreement aims for strengthening Immedica’s focus on ganaxolone, for the adjunctive treatment of epileptic seizures, by acquiring control of additional intellectual property rights.
Product Name : Ztalmy
Product Type : Other Small Molecule
Upfront Cash : $7.0 million
June 25, 2025
Lead Product(s) : Ganaxolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Ovid Therapeutics
Deal Size : $7.0 million
Deal Type : Agreement
Lead Product(s) : Pegzilarginase
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : KKR
Deal Size : Undisclosed
Deal Type : Acquisition
Kkr and Impilo Announce Strategic Partnership in Rare Disease Platform Immedica Pharma
Details : KKR and Impilo will support Immedica’s growth, including launching the approved ultra-orphan drug Loargys (pegzilarginase) and continuing in-licensing and M&A activities.
Product Name : Loargys
Product Type : Enzyme
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : Pegzilarginase
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : KKR
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
